Navigation Links
Following CMS Cuts to Reimbursement for Medical Errors, New Devices Aimed at Reducing Nosocomial Infections Emerge

WALTHAM, Mass., July 22 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the recent Centers for Medicare and Medicaid Services (CMS) cuts to reimbursement for hospital-acquired infections are resulting in adoption of antimicrobial-coated access devices, including dialysis catheters and central venous catheters (CVCs). MRG's US Markets for Vascular Access Devices 2009 report finds that usage of the antimicrobial-coated catheters will increase over the next five years as physicians take precautions against infections when using non-tunneled devices, which are placed directly into the vessel rather than buried under the skin.

A small portion of access catheters implanted in 2008 were equipped with antimicrobial coatings. However, this number of antimicrobial-coated CVC and dialysis catheter implantation procedures will rise at a compound annual growth rate of approximately 7% over the next five years as physicians recognize the ability of these coatings to combat the high risk of infection associated with non-tunneled catheters. The greater length and cuffed design of tunneled catheters provides a significant barrier to outside infection, whereas non-tunneled catheters are more susceptible to infection due to their design.

"The trend toward antimicrobial-coated catheters has been bolstered by CMS' April 2009 decision," says Stephanie LaBelle, Senior Analyst at MRG. "Although antimicrobial coatings were initially reserved for longer-indwelling CVCs and dialysis catheters, which are associated with higher risks of infection, 2009 saw the introduction of the first antimicrobial-coated peripherally inserted central venous catheter (PICC) from Cook Medical. The launch of the first antimicrobial PICC is the latest development in a more widespread trend that is exemplified by the rising popularity of antimicrobial-coated CVCs and dialysis catheters."

MRG's new report, US Markets for Vascular Access Devices 2009 provides detailed five-year market forecasts for the adoption of antimicrobial-coated CVCs and dialysis catheters, as well as insight into the release of the first antimicrobial-coated PICC. Additionally, the report provides full coverage of the short peripheral intravenous catheter, implantable port, and Huber needle markets.

About Millennium Research Group

Millennium Research Group (, a Decision Resources, Inc. company (, is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101

    Elizabeth Marshall
    Decision Resources Inc.

SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Treating depression may improve recovery of heart rate variability following coronary syndromes
2. Grocery Shoppers Are Following Stars to More Nutritious Choices
3. PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building
4. Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit
5. A New Study Links High Volume Pain Pumps with the Devastating and Painful Loss of Cartilage Following Arthroscopic Shoulder Surgery
6. ASPCA Provides Funding for Hay, Equine Expenses Following Outbreak of California Wildfires
7. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
8. Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions
9. The Blessing of a Brain Injury: Author Survives Injury to Brain Following Stroke, Uses Injury as Fuel to Overcome Odds
10. Stem cells train heart following heart attack
11. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 -- ... the company’s growing product line of food safety and seafood fraud prevention tools. ... nerka) – allow InstantLabs to offer fast, reliable species identification for the four ...
(Date:12/1/2015)... ... 01, 2015 , ... It’s official: Tattoo taboo is a thing of the ... among Millennials (a whopping one in three aged 18 to 25 is inked). As ... with their ink. In fact, RealSelf , the world’s largest community for learning ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus ... imaging results enhancements at the Radiological Society of North America (RSNA) 2015 annual ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December 1, ... fixed price per sprint agile development contract to support the National Geospatial-Intelligence Agency's ... years, provides software engineering, infrastructure, as well as operations and sustainment support to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: ... of chronic pain, announced today that the company will present ... held December 1-3 at the Luxe Sunset Boulevard Hotel in ... , CEO of Relmada Therapeutics, will present on Thursday, December ... . Please register at least 10 minutes ...
(Date:12/1/2015)... ANGELES , Dec. 1, 2015 CytRx ... development company specializing in oncology, today announced that it ... the company,s pivotal global Phase 3 clinical trial of ... (STS). Enrollment was originally estimated to be completed in Q1 ... being conducted under a Special Protocol Assessment from the ...
(Date:12/1/2015)... CHESTERBROOK, Pa. , Dec. 1, 2015 /PRNewswire/ ... leader, announced the launch of CareFront, a first-of-its-kind ... of patients diagnosed with cancer. Designed to be ... newly diagnosed cancer patients with resources for their ... costs. The program also offers tools to help ...
Breaking Medicine Technology: